标题
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
作者
关键词
Hepatitis C virus, Haplotypes, Mutagenesis, Viral replication, Substitution mutation, Cancer treatment, Mutation, Cell cultures
出版物
PLoS One
Volume 11, Issue 10, Pages e0164691
出版商
Public Library of Science (PLoS)
发表日期
2016-10-19
DOI
10.1371/journal.pone.0164691
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
- (2016) Isabel Gallego et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses
- (2016) Jonna B. Westover et al. ANTIVIRAL RESEARCH
- The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
- (2016) Christoph Sarrazin JOURNAL OF HEPATOLOGY
- Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives
- (2016) Tarik Asselah et al. LIVER INTERNATIONAL
- Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue
- (2016) Djamila Harouaka et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Involvement of a joker mutation in a polymerase-independent lethal mutagenesis escape mechanism
- (2016) Rubén Agudo et al. VIROLOGY
- Viral quasispecies complexity measures
- (2016) Josep Gregori et al. VIROLOGY
- Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
- (2016) Daouda Sissoko et al. PLOS MEDICINE
- Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection
- (2015) Graham R. Foster et al. GASTROENTEROLOGY
- Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
- (2015) David Wyles et al. HEPATOLOGY
- Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis
- (2015) Kentaro Yamada et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever
- (2015) Lisa Oestereich et al. JOURNAL OF INFECTIOUS DISEASES
- Therapy for hepatitis C genotype 3: moving forward
- (2015) M. Buti et al. JOURNAL OF VIRAL HEPATITIS
- Deep Sequencing and Phylogenetic Analysis of Variants Resistant to Interferon-Based Protease Inhibitor Therapy in Chronic Hepatitis Induced by Genotype 1b Hepatitis C Virus
- (2015) Mitsuaki Sato et al. JOURNAL OF VIROLOGY
- Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
- (2015) Christophe Hézode et al. LANCET
- Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study
- (2015) Anita Kohli et al. LANCET INFECTIOUS DISEASES
- Treatment of hepatitis C in difficult-to-treat patients
- (2015) Peter Ferenci Nature Reviews Gastroenterology & Hepatology
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
- (2015) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset
- (2015) David Safronetz et al. Scientific Reports
- Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection
- (2014) R. S. Koff ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment
- (2014) Dionna Scharton et al. ANTIVIRAL RESEARCH
- Inference with viral quasispecies diversity indices: clonal and NGS approaches
- (2014) Josep Gregori et al. BIOINFORMATICS
- Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
- (2014) Evguenia S. Svarovskaia et al. CLINICAL INFECTIOUS DISEASES
- Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C
- (2014) Gillian M. Keating DRUGS
- Daclatasvir plus sofosbuvir for HCV infection: An oral combination therapy with high antiviral efficacy
- (2014) Tarik Asselah JOURNAL OF HEPATOLOGY
- Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
- (2014) D. L. Wyles et al. JOURNAL OF VIRAL HEPATITIS
- Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
- (2014) J. Sheldon et al. JOURNAL OF VIROLOGY
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
- (2014) Eric Lawitz et al. LANCET
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ultra-Deep Pyrosequencing (UDPS) Data Treatment to Study Amplicon HCV Minor Variants
- (2014) Josep Gregori et al. PLoS One
- Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’
- (2014) Maria Buti et al. Expert Review of Gastroenterology & Hepatology
- Broad Spectrum Antiviral Activity of Favipiravir (T-705): Protection from Highly Lethal Inhalational Rift Valley Fever
- (2014) Amy L. Caroline et al. PLoS Neglected Tropical Diseases
- Favipiravir elicits antiviral mutagenesis during virus replication in vivo
- (2014) Armando Arias et al. eLife
- Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA Polymerase
- (2013) Hidehiro Sangawa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antiviral Efficacy of Favipiravir against Two Prominent Etiological Agents of Hantavirus Pulmonary Syndrome
- (2013) David Safronetz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Favipiravir (T-705), a novel viral RNA polymerase inhibitor
- (2013) Yousuke Furuta et al. ANTIVIRAL RESEARCH
- A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model
- (2013) Clara Ramírez et al. ANTIVIRAL RESEARCH
- Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
- (2013) James C. Sullivan et al. CLINICAL INFECTIOUS DISEASES
- Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice
- (2013) Donald F Smee et al. Future Virology
- Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients
- (2013) J. Dietz et al. JOURNAL OF VIROLOGY
- Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
- (2013) C. Perales et al. JOURNAL OF VIROLOGY
- T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro
- (2013) T. Baranovich et al. JOURNAL OF VIROLOGY
- Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
- (2013) Kris V Kowdley et al. LANCET
- Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
- (2013) Eric Lawitz et al. LANCET
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
- (2013) Eric Lawitz et al. LANCET INFECTIOUS DISEASES
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
- (2013) Edward J. Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extinction of Hepatitis C Virus by Ribavirin in Hepatoma Cells Involves Lethal Mutagenesis
- (2013) Ana M. Ortega-Prieto et al. PLoS One
- The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus Polymerase
- (2013) Zhinan Jin et al. PLoS One
- Favipiravir (T-705) Inhibits Junín Virus Infection and Reduces Mortality in a Guinea Pig Model of Argentine Hemorrhagic Fever
- (2013) Brian B. Gowen et al. PLoS Neglected Tropical Diseases
- Favipiravir (T-705) inhibits in vitro norovirus replication
- (2012) J. Rocha-Pereira et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Viral Quasispecies Evolution
- (2012) E. Domingo et al. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- Back to the future: revisiting HIV-1 lethal mutagenesis
- (2012) Michael J. Dapp et al. TRENDS IN MICROBIOLOGY
- Lethal Mutagenesis of Foot-and-Mouth Disease Virus Involves Shifts in Sequence Space
- (2011) C. Perales et al. JOURNAL OF VIROLOGY
- New Insights into the HCV Quasispecies and Compartmentalization
- (2011) Patrizia Farci SEMINARS IN LIVER DISEASE
- Effective Oral Favipiravir (T-705) Therapy Initiated after the Onset of Clinical Disease in a Model of Arenavirus Hemorrhagic Fever
- (2011) Michelle Mendenhall et al. PLoS Neglected Tropical Diseases
- Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system
- (2010) Christopher T Jones et al. NATURE BIOTECHNOLOGY
- A Multi-Step Process of Viral Adaptation to a Mutagenic Nucleoside Analogue by Modulation of Transition Types Leads to Extinction-Escape
- (2010) Rubén Agudo et al. PLoS Pathogens
- T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections
- (2009) Yousuke Furuta et al. ANTIVIRAL RESEARCH
- Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models
- (2009) Brian B. Gowen et al. ANTIVIRAL RESEARCH
- Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells
- (2009) D. F. Smee et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo
- (2009) J. M. Cuevas et al. JOURNAL OF VIROLOGY
- T-705 (favipiravir) activity against lethal H5N1 influenza A viruses
- (2009) M. Kiso et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activity of T-705 in a Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically Related Compound, T-1106
- (2008) J. G. Julander et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents
- (2008) J MORREY et al. ANTIVIRAL RESEARCH
- Therapeutically targeting RNA viruses via lethal mutagenesis
- (2008) Jason D Graci et al. Future Virology
- Molecular Characterization of a Dual Inhibitory and Mutagenic Activity of 5-Fluorouridine Triphosphate on Viral RNA Synthesis. Implications for Lethal Mutagenesis
- (2008) Rubén Agudo et al. JOURNAL OF MOLECULAR BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More